Lionel Yi Wen Leck

Lionel Yi Wen Leck

Auto-generated profile, based on publicly available information

Lionel Yi Wen Leck

Cancer Drug Resistance & Stem Cell Program, School of Medical Science, Faculty of Medicine and Health, The University of Sydney

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
LALina Al-Akra
Lina Al-Akra
DBDong-Hun Bae
Dong-Hun Bae
LLLionel Y.W. Leck
Lionel Y.W. Leck
DRDes R. Richardson
Des R. Richardson
Patric J. JanssonPatric J. Jansson
Patric J. Jansson

1 January 2020 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
KPKyung Chan Park
Kyung Chan Park
BGBekesho Geleta
Bekesho Geleta
LLLionel Yi Wen Leck
Lionel Yi Wen Leck
JPJasmina Paluncic
Jasmina Paluncic
SCShannon Chiang
Shannon Chiang
DRDes Richardson
Des Richardson
Considering the role of proto-oncogene c-Met (c-Met) in oncogenesis, we examined the effects of the metastasis suppressor, N-myc downstream-regulated gene-1 (NDRG1), and two NDRG1-inducing thiosemicarbazone-based agents, Dp44mT and DpC, on c-Met expression in DU145 and Huh7 cells. NDRG1 silencing without Dp44mT and DpC up-regulated c-Met expression, demonstrating that NDRG1 modulates c-Met levels. Dp44mT and DpC up-regulated NDRG1 by an iron-dependent mechanism and decreased c-Met levels, c-Met phosphorylation, and phosphorylation of its downstream effector, GRB2-associated binding protein 1 (GAB1). However, incubation with Dp44mT and DpC after NDRG1 silencing or silencing of the receptor tyrosine kinase inhibitor, mitogen-inducible gene 6 (MIG6), decreased c-Met and its phosphorylation, suggesting NDRG1- and MIG6-independent mechanism(s). Lysosomal inhibitors rescued the Dp44mT- and DpC-mediated c-Met down-regulation in DU145 cells. Confocal microscopy revealed that lysosomotropic agents and the thiosemicarbazones significantly increased co-localization between c-Met and lysosomal-associated membrane protein 2 (LAMP2). Moreover, generation of c-Met C-terminal fragment (CTF) and its intracellular domain (ICD) suggested metalloprotease-mediated cleavage. In fact, Dp44mT increased c-Met CTF while decreasing the ICD. Dp44mT and a γ-secretase inhibitor increased cellular c-Met CTF levels, suggesting that Dp44mT induces c-Met CTF levels by increasing metalloprotease activity. The broad metalloprotease inhibitors, EDTA and batimastat, partially prevented Dp44mT-mediated down-regulation of c-Met. In contrast, the ADAM inhibitor, TIMP metallopeptidase inhibitor 3 (TIMP-3), had no such effect, suggesting c-Met cleavage by another metalloprotease. Notably, Dp44mT did not induce extracellular c-Met shedding that could decrease c-Met levels. In summary, the thiosemicarbazones Dp44mT and DpC effectively inhibit oncogenic c-Met through lysosomal degradation and metalloprotease-mediated cleavage.

1 August 2020 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
Sumit SahniSumit Sahni
Sumit Sahni
Josef GillsonJosef Gillson
Josef Gillson
KPKyung Chan Park
Kyung Chan Park
SCShannon Chiang
Shannon Chiang
LLLionel Yi Wen Leck
Lionel Yi Wen Leck
DRDes Richardson
Des Richardson

1 May 2020 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
SKS. Krishan
S. Krishan
SSS. Sahni
S. Sahni
LLL.Y.W. Leck
L.Y.W. Leck
PJP.J. Jansson
P.J. Jansson
DRDes Richardson
Des Richardson

26 October 2020 in Future Drug Discovery
Verified
Journal Article
Open access
KSKatja Stefan
Katja Stefan
LLLionel Yi Wen Leck
Lionel Yi Wen Leck
VNVigneshwaran Namasivayam
Vigneshwaran Namasivayam
PBPablo Bascuñana
Pablo Bascuñana
MHMichael Li-Hsuan Huang
Michael Li-Hsuan Huang
Sven Marcel StefanSven Marcel Stefan
Sven Marcel Stefan

24 February 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
KBKarolina Borankova
Karolina Borankova
MKMaria Krchniakova
Maria Krchniakova
LLLionel Yw Leck
Lionel Yw Leck
JNJakub Neradil
Jakub Neradil
AKAdela Kubistova
Adela Kubistova
JSJan Skoda
Jan Skoda
High-risk neuroblastoma remains a clinically challenging childhood tumor with a 5-year survival of only 50%. Tumors overexpressing N-MYC or c-MYC oncoproteins define a group of MYC-driven high-risk neuroblastoma with the most dismal outcomes, mainly caused by treatment failure due to the emergence and regrowth of multidrug-resistant cancer cells. Specific mitochondrial processes have been implicated in the maintenance of aggressive stem-like phenotypes in various cancers. We have recently identified a novel mitochondria-mediated mechanism of neuroblastoma multidrug resistance. However, the potential of pharmacological targeting of mitochondria to overcome therapy resistance and stemness in neuroblastoma remains unclear. Here, we show that c-MYC/N-MYC-driven multidrug-resistant neuroblastoma cells are highly vulnerable to cell death induced by the inhibition of mitochondrial translation. In contrast with normal fibroblasts, doxycycline (DOXY)-mediated inhibition of mitochondrial ribosomes efficiently impaired the survival of neuroblastoma cells regardless of their multidrug resistance and stem-like phenotypes. Mechanistically, inhibiting mitochondrial translation induced the mitochondrial stress-activated integrated stress response (ISR) via the OMA1-eIF2α axis, which preceded neuroblastoma cell death. Strikingly, several oncoproteins associated with poor neuroblastoma prognosis, including c-MYC and N-MYC, were markedly downregulated upon ISR activation. Comparing models of various neuroectodermal tumors and normal fibroblasts, we identified high levels of phosphorylated c-MYC and N-MYC (indicating their activity and rapid turnover) as a factor that predetermines susceptibility of neuroblastoma cells to DOXY-induced cell death. Neuroblastoma cells failed to develop significant DOXY resistance over a long-term repeated (pulsed) selection pressure, further demonstrating mitochondrial protein balance as a clinically relevant vulnerability of cancer cells that rely on high MYC activity. Together, our findings provide insight into mitochondrial retrograde regulatory networks in the context of MYC dependence and demonstrate the mitochondrial translation machinery as a promising therapeutic target in multidrug-resistant MYC-driven neuroblastoma.